Skip to main content
Premium Trial:

Request an Annual Quote

EndoChoice to Promote Exagen Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Exagen Diagnostics said today that it has signed up EndoChoice to promote its genomic tests for bowel disorders to gastrointestinal doctors in the US.

EndoChoice, which specializes in gastroenterology, will market Exagen's gene expression tests for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Albuquerque, NM-based Exagen said in a statement.

Exagen CEO Scott Glenn said that the firm's eXaIBD and eXaIBS tests are sensitive and accurate at distinguishing IBD and IBS from other diseases

Exagen developed these tests using its Coperna computational tool and search engine, which identified genetic signatures associated with IBD and IBS.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.